




Brain Changes in Asymptomatic Individuals with Autosomal-dominant Alzheimer's Disease

Yakeel T. Quiroz, PhD


Massachusetts General Hospital, Harvard Medical School Grupo de Neurociencias, Universidad de Antioquia, Colombia



Age

Adapted from Sperling et al., 2011

A large extended family with early-onset AD in Antioquia, Colombia






- Autosomal dominant AD (ADAD): A unique opportunity to examine early AD-related changes in cognitively-normal individuals.
- Presenilin-1 (PSEN-1) mutation carriers develop early-onset AD with near 100% certainty.
- The Colombian kindred has a median age of mild cognitive impairment (MCI) at 44 years (95% CI +/- 2 years), and dementia at 49 years (95% CI +/- 2 years).
- Clinical, cognitive and biomarker similarities between ADAD and late-onset Sporadic AD.


Are there changes in the brain of mutation carriers years before the onset of AD symptoms?

What are the earliest brain changes associated with the predisposition to Alzheimer's disease?



Is brain hyperactivity one of the earliest signs of **AD-related** neurodegeneration?

Hippocampal Hyperactivation




Statistical Parametric Maps (SPMs) for the comparison PSEN1 mutation carriers versus controls for the contrast novel face-name pairs versus repeated face-name pairs. Color bar represents *t*-statistic values for all activated voxels within the anatomical mask.

Quiroz et al. (2010) Annals of Neurology

Younger group of carriers (18-25 years)

Carriers had greater right hippocampal and parahippocampal activation, and less precuneus and posterior cingulate deactivation







Figure 2. Reduced %BOLD suppression during face/name associated encoding in young pre-symptomatic E280A mutation carriers vs non-carriers (p=0.013).


Reiman, Quiroz et al. (2012), Lancet Neurology

Children/Adolescents (9-18 years)

Carriers had less parietal deactivation (Novel>Familiar)



Biomarker abnormalities in preclinical PSEN1 E280A carriers





Fleisher et al, 2012; 2015

Objective:

To characterize the relationship between amyloid burden and tau accumulation in the brains of *PSEN1* E280A mutation carriers and non-carriers from the Colombian kindred with autosomal dominant AD.

Hypotheses being tested:

- Abnormal levels of tau will be evident in the brains of asymptomatic PSEN1 mutation carriers.
- Amyloid- beta deposition will precede tau tangle formation both within and beyond the medial temporal lobe.

Methods

19 members of the Colombian kindred with *PSEN1* mutation traveled to Boston (USA) for tau PET using [F18] AV1451 and amyloid PET using [11C] PIB. Ten mutation carriers aged 28-44, and 9 non-carriers were included.

	MCI (n=2) (individual values)	Asymptomatic Carriers (n=8)	Noncarriers (n=9)	P-value
Age: mean (SD)	43, 44	33 (5)	38 (11)	0.28
Education	5, 11	9 (4)	11 (3)	0.13
MMSE	18, 26	28 (1.4)	29 (0.5)	0.23
CERAD Word List:				
Immediate Learning	8, 11	19 (5)	22 (4)	0.18
Delayed Recall	2, 7	7 (2)	8 (1)	0.21
Semantic Fluency (Animals)	14, 25	22 (6)	21 (4)	0.78

Aβ pathology measured with mean cortical 11C PiB for PSEN1 mutation carriers> controls

[18F] AV1451 binding for PSEN1 carriers and controls



Limitations:

Next Steps

- Characterize the relationship between tau deposition, decreased cognitive function, and neurodegenerative changes in preclinical ADAD.
- Compare the ability of tau biomarker measurements to predict subsequent cognitive decline in mutation carriers.
- Longitudinal study of tau biomarkers in preclinical ADAD.
- Compare findings from ADAD studies to preclinical late-onset AD (Harvard Aging Brain Study)

Acknowledgements:

Massachusetts General Hospital

Harvard Aging Brain Study

Reisa Sperling, MD Keith Johnson, MD Daniel Norton, PhD Dorene Rentz, PsyD Rebecca Amariglio, PhD Aaron Schultz, PhD Beth Mormino, PhD Kate Papp, PhD Patrizia Vannini, PhD Jennifer Gatchel, MD Gad Marshall, MD Jas Chhatwal, MD Bernard J.Hanseeuw, MD Molly Lapoint, BA Katie Munro, BA Sarah Aghjayan, BA Sehily Jaimes, BS Danielle Cosio, BS **Brendan Pulsifer**

Grupo de Neurociencias Universidad de Antioquia

Francisco Lopera, MD Ana Baena, BA Claudia Muñoz, BS Victoria Tirado, MS Margarita Giraldo, MD Natalia Acosta, MD Lina Velilla, MS Francisco Piedrahita, BS Carolina Ospina, MD Juliana Acosta, MD Paula Ospina, BA Silvia Rios, MD

Hospital Pablo Tobon Uribe

Sergio Alvarez, MD Andres Arbelaez, MD Feliza Restrepo, MD Manuel Marin, MD

Banner Alzheimer's Institute

Eric Reiman, MD Pierre Tariot, MD Kewei Chen, PhD Hillary Protas, PhD

Massachusetts Eye and Ear Institute

Joseph Arboleda, MD, PhD John Miller, MD Leo Kim, MD

PSEN1 Colombian families

Support: NIH Common Fund (Director's Early Independence Award), NIH NIA, Grimshaw Foundation, Colciencias-Colombia MGH ECOR (Claflin Distinguished Scholar, Physician-Scientist Development Award)



Yakeel T. Quiroz, Ph.D Email: yquiroz@mgh.harvard.edu

